Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone250-744-2487
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$460,000.00
Profitability
Miscellaneous
Employees39
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Aurinia Pharmaceuticals (NASDAQ:AUPH) Frequently Asked Questions
What is Aurinia Pharmaceuticals' stock symbol?
Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH."
How were Aurinia Pharmaceuticals' earnings last quarter?
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) released its earnings results on Tuesday, August, 6th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by $0.02. The biotechnology company earned $0.03 million during the quarter, compared to analyst estimates of $0.05 million. Aurinia Pharmaceuticals had a negative net margin of 13,231.97% and a negative return on equity of 50.08%. View Aurinia Pharmaceuticals' Earnings History.
When is Aurinia Pharmaceuticals' next earnings date?
What price target have analysts set for AUPH?
6 Wall Street analysts have issued 12 month price objectives for Aurinia Pharmaceuticals' shares. Their predictions range from $11.00 to $25.00. On average, they anticipate Aurinia Pharmaceuticals' stock price to reach $16.50 in the next year. This suggests a possible upside of 172.7% from the stock's current price. View Analyst Price Targets for Aurinia Pharmaceuticals.
What is the consensus analysts' recommendation for Aurinia Pharmaceuticals?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aurinia Pharmaceuticals.
What are Wall Street analysts saying about Aurinia Pharmaceuticals stock?
Here are some recent quotes from research analysts about Aurinia Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company's lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada. " (7/16/2019)
- 2. HC Wainwright analysts commented, "Buy ILJIN seeks effective control of Aurinia, or at least substantial influence, wholly disproportionate to its current holdings. Over the weekend, Aurinia’s largest shareholder (about 14% S/O), ILJIN SNT Co., Ltd. (private; Seoul, South Korea) launched a proxy contest to elect at least 3 directors to the upcoming Annual General Meeting (AGM) to be held on Wednesday, June 26, 2019. ILJIN is a life science-focused investment fund with a portfolio of positions in about 12 companies (according to its website), including Aurinia which appears to be its largest and longest holding, with a total of about $58M invested since 2010, according to ILJIN." (6/4/2019)
Has Aurinia Pharmaceuticals been receiving favorable news coverage?
News stories about AUPH stock have been trending somewhat negative on Monday, InfoTrie reports. The research firm ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Aurinia Pharmaceuticals earned a daily sentiment score of -1.3 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Aurinia Pharmaceuticals.
Who are some of Aurinia Pharmaceuticals' key competitors?
Some companies that are related to Aurinia Pharmaceuticals include Agios Pharmaceuticals (AGIO), Akcea Therapeutics (AKCA), Portola Pharmaceuticals (PTLA), Xencor (XNCR), Cambrex (CBM), Zai Lab (ZLAB), Ligand Pharmaceuticals (LGND), Deciphera Pharmaceuticals (DCPH), Zogenix (ZGNX), Uniqure (QURE), Insmed (INSM), Prestige Consumer Healthcare (PBH), Tricida (TCDA), Apellis Pharmaceuticals (APLS) and Corcept Therapeutics (CORT).
What other stocks do shareholders of Aurinia Pharmaceuticals own?
Who are Aurinia Pharmaceuticals' key executives?
Aurinia Pharmaceuticals' management team includes the folowing people:
- Mr. Michael R. Martin, Co-Founder & COO
- Mr. Dennis Bourgeault CPA, C.A., CFO & Sec.
- Mr. Robert B. Huizinga RN NNC, MSc(Epi), CNeph(C), Exec. VP of Corp. Devel.
- Dr. Richard M. Glickman, Advisor (Age 61)
- Dr. Neil Solomons M.D., Chief Medical Officer
Who are Aurinia Pharmaceuticals' major shareholders?
Aurinia Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Orbimed Advisors LLC (3.85%), Vivo Capital LLC (2.08%), BlackRock Inc. (1.00%), D. E. Shaw & Co. Inc. (0.43%), Candriam Luxembourg S.C.A. (0.14%) and Swiss National Bank (0.12%).
Which institutional investors are selling Aurinia Pharmaceuticals stock?
AUPH stock was sold by a variety of institutional investors in the last quarter, including D. E. Shaw & Co. Inc., Renaissance Technologies LLC, Candriam Luxembourg S.C.A. and Morgan Stanley.
Which institutional investors are buying Aurinia Pharmaceuticals stock?
AUPH stock was bought by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Orbimed Advisors LLC, BlackRock Inc., Wells Fargo & Company MN, Point72 Asset Management L.P., Swiss National Bank, UBS Asset Management Americas Inc. and A.R.T. Advisors LLC.
How do I buy shares of Aurinia Pharmaceuticals?
Shares of AUPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Aurinia Pharmaceuticals' stock price today?
One share of AUPH stock can currently be purchased for approximately $6.05.
How big of a company is Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals has a market capitalization of $555.57 million and generates $460,000.00 in revenue each year. The biotechnology company earns $-64,120,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis. Aurinia Pharmaceuticals employs 39 workers across the globe.View Additional Information About Aurinia Pharmaceuticals.
What is Aurinia Pharmaceuticals' official website?
How can I contact Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals' mailing address is 1203-4464 MARKHAM STREET, VICTORIA A1, V8Z 7X8. The biotechnology company can be reached via phone at 250-744-2487 or via email at [email protected]
MarketBeat Community Rating for Aurinia Pharmaceuticals (NASDAQ AUPH)
MarketBeat's community ratings are surveys of what our community members think about Aurinia Pharmaceuticals and other stocks. Vote "Outperform" if you believe AUPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AUPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
